Rakesh Gopinathannair, Renee M Sullivan, Brian Olshansky. Show Affiliations »
Abstract
Entities: Disease
Mesh: See more » Adrenergic beta-Antagonists/therapeutic useAngiotensin II Type 1 Receptor Blockers/therapeutic useAntihypertensive Agents/therapeutic useAtenolol/therapeutic useAtrial Fibrillation/etiologyAtrial Fibrillation/physiopathologyAtrial Fibrillation/prevention & controlElectrocardiographyHeart Rate/drug effectsHumansHypertension/complicationsHypertension/drug therapyHypertension/physiopathologyHypertrophy, Left Ventricular/etiologyHypertrophy, Left Ventricular/physiopathologyHypertrophy, Left Ventricular/prevention & controlIncidenceLosartan/therapeutic useReference ValuesRisk AssessmentRisk FactorsTachycardia/physiopathologyTime FactorsTreatment Outcome
Substances: See more » Adrenergic beta-AntagonistsAngiotensin II Type 1 Receptor BlockersAntihypertensive AgentsAtenololLosartan
Year: 2008 PMID: 19808425 DOI: 10.1161/CIRCEP.108.835264
Source DB: PubMed Journal: Circ Arrhythm Electrophysiol ISSN: 1941-3084